165 related articles for article (PubMed ID: 37805343)
1. Adequacy of cytology and small biopsy samples obtained with rapid onsite evaluation (ROSE) for predictive biomarker testing in non-small cell lung cancer.
Hendry S; Mamotte L; Mesbah Ardakani N; Leslie C; Tesfai Y; Grieu-Iacopetta F; Izaac K; Singh S; Ardakani R; Thomas M; Giardina T; Robinson C; Frost F; Amanuel B
Pathology; 2023 Dec; 55(7):917-921. PubMed ID: 37805343
[TBL] [Abstract][Full Text] [Related]
2. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.
Gürün Kaya A; Çiledağ A; Erol S; Öz M; Doğan Mülazımoğlu D; Işık Ö; Özakıncı H; Çiftçi F; Şen E; Ceyhan K; Kaya A; Karnak D; Çelik G; İsmail S
Scott Med J; 2022 Feb; 67(1):18-27. PubMed ID: 35147461
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis in cytological samples obtained by endobronchial or oesophageal ultrasound guided needle aspiration in non-small cell lung cancer.
Centeno C; Serra Mitja P; Avila M; Carcereny E; Muñoz-Mármol AM; Moran T; Castellà E; Sanz-Santos J; García Olivé I; Ramirez Serrano JL; Rosell Gratacos A; Andreo García F
Pulmonology; 2022; 28(1):28-33. PubMed ID: 32507497
[TBL] [Abstract][Full Text] [Related]
5. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
6. Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?
Yarmus L; Akulian J; Gilbert C; Feller-Kopman D; Lee HJ; Zarogoulidis P; Lechtzin N; Ali SZ; Sathiyamoorthy V
Ann Am Thorac Soc; 2013 Dec; 10(6):636-43. PubMed ID: 24079724
[TBL] [Abstract][Full Text] [Related]
7. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration samples for programmed death ligand-1 testing in non-small cell lung cancer, the Bristol experience.
Hardy J; Bhatt N; Medford ARL
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e32-e38. PubMed ID: 33870634
[TBL] [Abstract][Full Text] [Related]
8. Handling and standardization of EBUS needle aspiration in NSCLC patients: The value of the cell block, a monoinstitutional experience.
Parente P; Carbonelli C; Biancofiore G; Sukthi A; Di Micco CM; Vairo M; Fuso P; Taurchini M; Graziano P
Thorac Cancer; 2022 Sep; 13(17):2480-2488. PubMed ID: 35868633
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
Biswas A; Leon ME; Drew P; Fernandez-Bussy S; Furtado LV; Jantz MA; Mehta HJ
Diagn Cytopathol; 2018 May; 46(5):378-383. PubMed ID: 29476608
[TBL] [Abstract][Full Text] [Related]
10. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
12. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
[TBL] [Abstract][Full Text] [Related]
13. Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer.
Esterbrook G; Anathhanam S; Plant PK
Lung Cancer; 2013 Apr; 80(1):30-4. PubMed ID: 23312886
[TBL] [Abstract][Full Text] [Related]
14. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F
J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
16. Adequacy of EBUS-TBNA specimen for mutation analysis of lung cancer.
Cicek T; Ozturk A; Yılmaz A; Aktas Z; Demirag F; Akyurek N
Clin Respir J; 2019 Feb; 13(2):92-97. PubMed ID: 30582673
[TBL] [Abstract][Full Text] [Related]
17. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.
Perrotta F; Nankivell M; Adizie JB; Maqsood U; Elshafi M; Jafri S; Lerner AD; Woolhouse I; Munavvar M; Evison M; Booton R; Baldwin DR; Janes SM; Kerr KM; Bianco A; Yarmus L; Navani N
Chest; 2020 Sep; 158(3):1230-1239. PubMed ID: 32428509
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.
Stoy SP; Rosen L; Mueller J; Murgu S
Cancer Cytopathol; 2018 Feb; 126(2):122-128. PubMed ID: 29053224
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
[TBL] [Abstract][Full Text] [Related]
20. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
